Treatment of Edema and Increased Capillary Filtration in Venous Hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a Clinical, Prospective, Placebo-controlled, Randomized, Dose-ranging Trial
Overview
Affiliations
Unlabelled: The variation of capillary filtration rate (CFR) and ankle edema (AE) were evaluated in three groups of patients with venous hypertension with ambulatory venous pressure > 42 mmHg and in healthy subjects before and after treatment for four weeks with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides), a venoactive drug acting on the microcirculation and on capillary permeability. Group A (30 patients) was treated with HR 500 mg tid; group B (30 patients) was treated with 1 g tid; group C (30 patients) was treated with placebo; group D (10 healthy subjects) was treated with HR 1 g/day in a randomised study. CFR was assessed by venous occlusion plethysmography. Subjective symptoms of venous hypertension were assessed by an analogue scale line considering four symptoms: swelling sensation, restless lower extremity, pain and cramps, and tiredness.
Results: There were no significant differences for sex and age distribution among the groups; no significant differences were found for ambulatory venous pressure and refilling time and parameters of venous hypertension among groups. There was a significant difference between normal subjects and patients. There were no drop-outs and observed intolerance. In group A, there was a significant decrease of CFR (P < 0.01) after treatment. In group B (2 g/day), the decrease was greater than that in group A (P < 0.05). In group C (placebo) there was no significant difference before or after treatment. The variations in analogue score was higher with the higher dosage. The score of group A fell from 7.8 (SD 1.3) to 4 (1). Group B's score fell from 7.9 (2) to 3.1 (1.2). In group C (placebo) there was no change. The decrease in the score in the groups of patients was correlated with the variation in edema and CFR.
Conclusion: HR is effective in venous edema and hypertension. Its effects are dose-related.
Phlebotonics for venous insufficiency.
Martinez-Zapata M, Vernooij R, Simancas-Racines D, Uriona Tuma S, Stein A, Moreno Carriles R Cochrane Database Syst Rev. 2020; 11:CD003229.
PMID: 33141449 PMC: 8094625. DOI: 10.1002/14651858.CD003229.pub4.
Steinbruch M, Nunes C, Gama R, Kaufman R, Gama G, Suchmacher Neto M Int J Vasc Med. 2020; 2020:4237204.
PMID: 32206351 PMC: 7081038. DOI: 10.1155/2020/4237204.
Phlebotonics for venous insufficiency.
Martinez-Zapata M, Vernooij R, Uriona Tuma S, Stein A, Moreno R, Vargas E Cochrane Database Syst Rev. 2016; 4:CD003229.
PMID: 27048768 PMC: 7173720. DOI: 10.1002/14651858.CD003229.pub3.
Stuard S, Cesarone M, Belcaro G, Dugall M, Ledda A, Cacchio M Int J Angiol. 2012; 17(3):143-8.
PMID: 22477419 PMC: 2727765. DOI: 10.1055/s-0031-1278299.